2026 Q2 -tulosraportti
Vain PDF
6 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 30 | - | - | ||
| 5 000 | - | - | ||
| 100 | - | - | ||
| 1 000 | - | - | ||
| 25 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 26.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 27.8. | ||
2026 Q1 -tulosraportti 28.5. | ||
2025 Q4 -tulosraportti 30.10.2025 | ||
2025 Q3 -tulosraportti 24.7.2025 | ||
2025 Q2 -tulosraportti 25.4.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·18.8.it would be strange if one makes these investments if one doesn't have a good feeling for what's to come. fair chance that they raise a significant amount in Asia - the upside is magnificent, the downside extremely limited in comparison therewith. why sell today?
·18.8.Exciting news – and an exciting time to announce them! Japan could be a gamechanger for NextCell. The challenge is not only to prove that NXTCL works – it is also to finance further development. The company's current plan is for Phase III to be initiated when a commercial partner is in place. NextCell has been selected for JETRO's selective accelerator program, which provides structured access to Japanese pharmaceutical companies, investors, and other relevant stakeholders. Now, as the only Swedish company, they have also been selected for the EU-Japan Biotech Business Mission 2026, where the focus is precisely on business development and partnering. The timing could hardly be more exciting. NextCell enters the autumn with upcoming NXTCL-data, BIOHK, BioJapan, and direct partnering activities in Japan. If the Young study delivers strong results, the company could thus have a significantly stronger data package at precisely the time when potential partners are met. And an Asian partner could potentially change the entire equation. A partner can help finance further clinical development, and a potential licensing agreement could potentially involve upfront payments, milestone payments, and royalties. At the same time, a strong industrial partner will be an important external validation of NXTCL. It is not yet a partnership agreement. But today's news makes it clear that targeted efforts are being made to translate their Asia strategy into exactly that.- ·6.7.downside 50% - upside 1.000%. decent odds. but the probability of the downside is likely higher than for the upside. but if not..........interesting risk/reward. very skilled researchers behind the company. as jalokin rightly points out - biotech is however always associated with high risk. I'm however putting a stake on NextCell becoming a winner in the second half of 2026.
- ·1.7.I personally think it's worth asking oneself if it makes sense to sell just before the biggest known share price driver in a long time. We already know that: ProTrans has shown long-term effect in adult patients. The company has announced that the next important data from ProTrans-Young are expected after summer. The entire case seems to be centered around precisely those results. Of course, this doesn't mean the data will be good – biotech is always associated with high risk. But if one has held the stock through the long waiting period, it seems a bit strange to sell a few months before the event that could potentially change the entire valuation. If data disappoints, the stock might fall, but if data are strong, the market's assessment can change significantly, and it can simultaneously increase the likelihood of a partnership agreement or other strategic opportunities. For me, it's therefore not about being certain of the outcome – it's about the risk/reward ratio appearing most interesting precisely leading up to the readout. After that, one can make a decision based on actual data instead of speculation. This is, of course, only my own assessment and not a buy recommendation.
- 6.5.It doesn't seem like anyone is on board with everything going fantastically.. I think the stock price is going down.. is it due to a lack of patience?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 18 909 | 18 909 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 18 909 | 18 909 | 0 | 0 |
2026 Q2 -tulosraportti
Vain PDF
6 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·18.8.it would be strange if one makes these investments if one doesn't have a good feeling for what's to come. fair chance that they raise a significant amount in Asia - the upside is magnificent, the downside extremely limited in comparison therewith. why sell today?
- ·18.8.Exciting news – and an exciting time to announce them! Japan could be a gamechanger for NextCell. The challenge is not only to prove that NXTCL works – it is also to finance further development. The company's current plan is for Phase III to be initiated when a commercial partner is in place. NextCell has been selected for JETRO's selective accelerator program, which provides structured access to Japanese pharmaceutical companies, investors, and other relevant stakeholders. Now, as the only Swedish company, they have also been selected for the EU-Japan Biotech Business Mission 2026, where the focus is precisely on business development and partnering. The timing could hardly be more exciting. NextCell enters the autumn with upcoming NXTCL-data, BIOHK, BioJapan, and direct partnering activities in Japan. If the Young study delivers strong results, the company could thus have a significantly stronger data package at precisely the time when potential partners are met. And an Asian partner could potentially change the entire equation. A partner can help finance further clinical development, and a potential licensing agreement could potentially involve upfront payments, milestone payments, and royalties. At the same time, a strong industrial partner will be an important external validation of NXTCL. It is not yet a partnership agreement. But today's news makes it clear that targeted efforts are being made to translate their Asia strategy into exactly that.
- ·6.7.downside 50% - upside 1.000%. decent odds. but the probability of the downside is likely higher than for the upside. but if not..........interesting risk/reward. very skilled researchers behind the company. as jalokin rightly points out - biotech is however always associated with high risk. I'm however putting a stake on NextCell becoming a winner in the second half of 2026.
- ·1.7.I personally think it's worth asking oneself if it makes sense to sell just before the biggest known share price driver in a long time. We already know that: ProTrans has shown long-term effect in adult patients. The company has announced that the next important data from ProTrans-Young are expected after summer. The entire case seems to be centered around precisely those results. Of course, this doesn't mean the data will be good – biotech is always associated with high risk. But if one has held the stock through the long waiting period, it seems a bit strange to sell a few months before the event that could potentially change the entire valuation. If data disappoints, the stock might fall, but if data are strong, the market's assessment can change significantly, and it can simultaneously increase the likelihood of a partnership agreement or other strategic opportunities. For me, it's therefore not about being certain of the outcome – it's about the risk/reward ratio appearing most interesting precisely leading up to the readout. After that, one can make a decision based on actual data instead of speculation. This is, of course, only my own assessment and not a buy recommendation.
- 6.5.It doesn't seem like anyone is on board with everything going fantastically.. I think the stock price is going down.. is it due to a lack of patience?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 30 | - | - | ||
| 5 000 | - | - | ||
| 100 | - | - | ||
| 1 000 | - | - | ||
| 25 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 26.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 27.8. | ||
2026 Q1 -tulosraportti 28.5. | ||
2025 Q4 -tulosraportti 30.10.2025 | ||
2025 Q3 -tulosraportti 24.7.2025 | ||
2025 Q2 -tulosraportti 25.4.2025 |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 18 909 | 18 909 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 18 909 | 18 909 | 0 | 0 |
2026 Q2 -tulosraportti
Vain PDF
6 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 26.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 27.8. | ||
2026 Q1 -tulosraportti 28.5. | ||
2025 Q4 -tulosraportti 30.10.2025 | ||
2025 Q3 -tulosraportti 24.7.2025 | ||
2025 Q2 -tulosraportti 25.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·18.8.it would be strange if one makes these investments if one doesn't have a good feeling for what's to come. fair chance that they raise a significant amount in Asia - the upside is magnificent, the downside extremely limited in comparison therewith. why sell today?
- ·18.8.Exciting news – and an exciting time to announce them! Japan could be a gamechanger for NextCell. The challenge is not only to prove that NXTCL works – it is also to finance further development. The company's current plan is for Phase III to be initiated when a commercial partner is in place. NextCell has been selected for JETRO's selective accelerator program, which provides structured access to Japanese pharmaceutical companies, investors, and other relevant stakeholders. Now, as the only Swedish company, they have also been selected for the EU-Japan Biotech Business Mission 2026, where the focus is precisely on business development and partnering. The timing could hardly be more exciting. NextCell enters the autumn with upcoming NXTCL-data, BIOHK, BioJapan, and direct partnering activities in Japan. If the Young study delivers strong results, the company could thus have a significantly stronger data package at precisely the time when potential partners are met. And an Asian partner could potentially change the entire equation. A partner can help finance further clinical development, and a potential licensing agreement could potentially involve upfront payments, milestone payments, and royalties. At the same time, a strong industrial partner will be an important external validation of NXTCL. It is not yet a partnership agreement. But today's news makes it clear that targeted efforts are being made to translate their Asia strategy into exactly that.
- ·6.7.downside 50% - upside 1.000%. decent odds. but the probability of the downside is likely higher than for the upside. but if not..........interesting risk/reward. very skilled researchers behind the company. as jalokin rightly points out - biotech is however always associated with high risk. I'm however putting a stake on NextCell becoming a winner in the second half of 2026.
- ·1.7.I personally think it's worth asking oneself if it makes sense to sell just before the biggest known share price driver in a long time. We already know that: ProTrans has shown long-term effect in adult patients. The company has announced that the next important data from ProTrans-Young are expected after summer. The entire case seems to be centered around precisely those results. Of course, this doesn't mean the data will be good – biotech is always associated with high risk. But if one has held the stock through the long waiting period, it seems a bit strange to sell a few months before the event that could potentially change the entire valuation. If data disappoints, the stock might fall, but if data are strong, the market's assessment can change significantly, and it can simultaneously increase the likelihood of a partnership agreement or other strategic opportunities. For me, it's therefore not about being certain of the outcome – it's about the risk/reward ratio appearing most interesting precisely leading up to the readout. After that, one can make a decision based on actual data instead of speculation. This is, of course, only my own assessment and not a buy recommendation.
- 6.5.It doesn't seem like anyone is on board with everything going fantastically.. I think the stock price is going down.. is it due to a lack of patience?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 30 | - | - | ||
| 5 000 | - | - | ||
| 100 | - | - | ||
| 1 000 | - | - | ||
| 25 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 18 909 | 18 909 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 18 909 | 18 909 | 0 | 0 |